Anika Therapeutics, Inc.
NASDAQAnika Therapeutics delivered a Q1 earnings beat this morning, and the market sold it anyway — a classic "buy the rumour, sell the fact" reaction that puts the focus squarely on what comes next from the FDA. The numbers were genuinely good. Q1 adjusted EPS came in at $0.27, well ahead of the consensus estimate of negative $0.16, with revenue of $29.6 million beating the $28.1…
Snapshot as of 11 May 2026
Anika Therapeutics delivered a Q1 earnings beat this morning, and the market sold it anyway — a classic "buy the rumour, sell the fact" reaction that puts the focus squarely on what comes next from the FDA. The numbers…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ANIK — free to start on ORTEX.
Sign up for free →Open ANIK on ORTEX